Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 1453 other investors.
Redeyes view on the Q4 report. The report was weak, and the challenges continue to affect the company negatively. We lower our expectations for 2023e as we do not see the difficulties fading in the short term. The development for the second half of 2022 was a reversal compared to a relatively solid development during the year’s first half. Considering the deviation from our expectations and continued headwinds going into 2023e, we have adjusted our estimates for 2023e and for the following years as well.
Organic sales growth: Q4, 2022: -17% (25)
EBITDA margin:Q4, 2022: 32% (37)
Summary, October 1-December 31, 2022
CellaVision AB (publ) will publish the report for the fourth quarter 2022, on February 7, 2023 at 7:20 CET. The report will be available at ir.cellavision.com
In connection with the release of the interim report analysts, investors and media are hereby invited to a conference call and webcast at 11:00 CET where Simon Østergaard, President & CEO, will present and comment the report. The presentation will be in English.
CellaVision presents at the Carlsquare Nordic Life Science investor day. The full presentation, including the Q&A-session is available at the Carlsquare website: https://carlsquare.com/sv/cellavision-at-carlsquare-nordic-life-science-investor-day/
Ahead of the Annual General Meeting 2023, the Nomination Committee consists of:
Emil Hjalmarsson has been appointed Chairman of the Nomination Committee.
On Thursday November 17 Carlsquare will host a Life science themed Investor day in collaboration with Infront Direkt Studios. We would like to welcome interested investors to attend. CellaVision is set to start its presentation at 13:00 and will be available to answer your questions. Do you wish to attend?
Redeyes view on the Q3 report. The report was weak, in our opinion, even considering the challenges in the market and the typical seasonal fluctuation. Up to this point, the development in 2022 has been solid.
Organic sales growth: Q3, 2022: -3% (52)
EBITDA margin:Q3, 2022: 21% (32)
Summary, July 1-September 30, 2022
CellaVision AB (publ) will publish the Interim report for the third quarter, on October 26, 2022 at 7:20 CEST. The report will be available at ir.cellavision.com
In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CEST where Simon Østergaard, President & CEO, will present and comment the report.
On July 27, 2022, CellaVision® announces the launch of DIFF-Line ™ by CellaVision, a new workflow solution for low-volume hematology laboratories, at the AACC convention in Chicago.
DIFF-Line ™ by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision® DC-1, RAL® SmearBox, and RAL® StainBox.